Developer docs
API playgroundTry for free, no card

Search company profiles

TrilliumBiO

Full company profile

uuid000bebz

Namestring
TrilliumBiO
Legal namestring
Trillium Health, LLC
Websiteurl
trilliumbio.com
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diagnostic test development, companion diagnostics, biomarker discovery services, clinical laboratory testing, rare disease diagnostics
Industry4 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAE
Clinical Chemistry, Hematology & Coagulation Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Diagnostic Laboratory Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Laboratory Diagnostic Testing Services
TypeManaged Services
Description

TrilliumBiO processes over 500,000 samples annually through its multi-accredited, CLIA-certified laboratory. Revenue is generated through diagnostic testing fees charged to healthcare providers, health systems, and pharmaceutical partners for validated assay services.

trilliumbio.com
2Pharmaceutical and Biotech Partnership Services
TypeProfessional Services
Description

The company collaborates with biotech and pharma partners to develop, validate, and commercialize companion diagnostic assays. These partnerships involve co-development, assay validation, and clinical laboratory services supporting partner therapeutic development programs and regulatory submissions.

trilliumbio.com
3Companion Diagnostic Development and Licensing
TypeLicensing Royalties
Description

TrilliumBiO develops and validates novel diagnostic tests in conjunction with biopharma partners, commercializing them as Laboratory Developed Tests (LDT) through its own laboratory infrastructure, generating licensing and development fees from partners.

trilliumbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1No-cost diagnostic test for aPAP (autoimmune Pulmonary Alveolar Proteinosis)
ModelOtherBilling cadencePay-as-you-go
Notes

The aPAP ClearPath GM-CSF autoantibody blood test is offered at no cost to patients. TrilliumBiO operates as the CLIA-certified laboratory partner developing and processing the test for Savara Inc. Specific laboratory service fees are not publicly disclosed.

trilliumbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Oncular™
Description

A uveal melanoma monitoring solution combining personalized digital PCR with cloud-based ctDNA analysis to track molecular residual disease, longitudinal ctDNA trends, and early molecular signals of treatment response or disease progression in metastatic uveal melanoma patients.

trilliumbio.com
+2 more records
Core offering1 text field

TrilliumBiO is a life sciences company that develops, validates, and commercializes diagnostic assays (Laboratory Developed Tests) through its multi-accredited, CLIA-certified, CAP-accredited, ISO 15189-accredited laboratory in Rockville, MD. It partners with biotech and pharmaceutical companies to co-develop companion diagnostics and provides biomarker discovery, assay validation, and clinical testing services to physicians and patients nationwide. Its portfolio includes specialized tests for autoimmune pulmonary alveolar proteinosis (aPAP ClearPath), alpha-1 antitrypsin deficiency (AlphaID), and uveal melanoma monitoring (Oncular), processing over 500,000 samples annually.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • GM-CSF autoantibody assay achieved 100% clinical accuracy in a cohort of 40 subjects (negative cohort n=20, positive cohort n=20)
+4 more records
Product overview1 text field

TrilliumBiO is a biomarker discovery and translational diagnostics company operating a multi-accredited, CLIA-certified laboratory that has launched over 100 assays and processes over 500,000 samples annually. The company operates a platform-plus-services model offering a portfolio of specialized diagnostic tests including Oncular™ for uveal melanoma monitoring, AlphaID™ for alpha-1 antitrypsin deficiency screening, and aPAP ClearPath™ for autoimmune pulmonary alveolar proteinosis detection. Additional offerings include VEGF-D assay for LAM diagnosis, EMR integration workflows, and custom biomarker discovery services. The company collaborates with biopharma partners, academic medical centers, foundations, and patient advocacy groups to translate scientific discoveries into patient-ready diagnostics.

Product and service4 records
1Oncular™
CategoryMolecular Oncology Diagnostics
Description

A Laboratory Developed Test for uveal melanoma monitoring that provides real-time, quantitative assessment of circulating tumor DNA (ctDNA) from a blood draw, delivering molecular residual disease status, longitudinal ctDNA trends, and early molecular signals of treatment response or disease progression using personalized digital PCR with cloud-based data analysis.

2AlphaID™
CategoryPulmonology / Rare Disease Diagnostics
Description

A diagnostic screening program for alpha-1 antitrypsin deficiency (AATD) that combines dried blood spot or buccal swab specimens with quantitative AAT serum measurement via immunoturbidimetry, detecting 14 clinically relevant SERPINA1 allelic variants including rare null alleles and compound heterozygotes missed by conventional testing.

3aPAP ClearPath™
CategoryPulmonology / Rare Disease Diagnostics
Description

A GM-CSF autoantibody blood test for diagnosis of autoimmune pulmonary alveolar proteinosis (aPAP), available as both a serum-based assay and a dried blood spot (DBS) test that requires only a finger-prick sample. Developed and processed in partnership with Savara Inc., offered as a no-cost diagnostic tool to patients.

4VEGF-D Assay
CategoryPulmonology / Rare Disease Diagnostics
Description

A biomarker assay for lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, used for diagnosis and monitoring of LAM patients.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-09
Description

TrilliumBiO and Oncobit formed a strategic partnership to bring Oncobit's uveal melanoma monitoring solution to the United States. TrilliumBiO implements Oncobit's proprietary Personalized Monitoring (PM) platform, including cloud-based data interpretation software, to track circulating tumor DNA (ctDNA) dynamics in metastatic uveal melanoma patients. The partnership makes Oncobit's assay available nationwide through TrilliumBiO's multi-accredited laboratory, providing physicians with molecular residual disease information to support precise therapy decisions. In May 2026, the companies launched Oncular™ as the resulting product.

2BioHub Maryland (Maryland Tech Council)
Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2025-11-03
Description

TrilliumBiO joined BioHub Maryland, the workforce initiative powered by Maryland Tech Council, as an Elite Partner. This collaboration supports strengthening Maryland's life sciences ecosystem by highlighting career paths in laboratory medicine and expanding access to high-impact research and development opportunities. BioHub Maryland is a workforce initiative helping life sciences companies grow by showcasing career opportunities and providing access to talent and strategic resources.

trilliumbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-29
Description

TrilliumBiO and T-NeuroDx announced a strategic collaboration to advance the development and commercialization of blood-based biomarker diagnostics for Alzheimer's disease. The partnership combines TrilliumBiO's diagnostic assay development and clinical validation expertise with T-NeuroDx's biomarker science for Alzheimer's disease pathology. The companies aim to co-develop and validate blood-based biomarkers that can support earlier diagnosis, commercializing T-Neuro's technology as a Lab Developed Test (LDT). The initiative includes clinical studies across diverse populations to support regulatory submissions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-21
Description

TrilliumBiO partnered with Savara Inc. as a CLIA-certified laboratory to develop and process the aPAP ClearPath GM-CSF autoantibody blood test for diagnosis of autoimmune pulmonary alveolar proteinosis (aPAP). The partnership developed both the serum-based assay and a dried blood spot (DBS) version using the ADX100 serum separator card. The test was offered as a simple, no-cost, noninvasive diagnostic tool to help confirm or rule out aPAP, addressing an estimated diagnosed prevalence of 7 cases per million in the US.

5Grifols Shared Service North America
Strategic tierCoreTypeTechnology or Integration
Description

TrilliumBiO collaborates with Grifols on the AlphaID screening program for alpha-1 antitrypsin deficiency. The partnership uses Grifols' FDA-cleared AAT genotyping assay (Progenika Biopharma, Spain), which detects 14 clinically relevant SERPINA1 allelic variants. TrilliumBiO provides dried blood spot and buccal swab specimen processing, quantitative AAT measurement via immunoturbidimetry, and nationwide testing logistics.

trilliumbio.com
6Cincinnati Translational Pulmonary Science Center
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

TrilliumBiO developed the dried blood spot GM-CSF autoantibody assay in collaboration with Savara Inc. and Cincinnati Translational Pulmonary Science Center. The study involved three independent analyses demonstrating robust analytical precision and strong correlations between serum from venipuncture and DBS samples.

trilliumbio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty clinical laboratory focused on oncology-focused diagnostic testing and biomarker services for pharma partners. Closely comparable to TrilliumBiO in offering companion diagnostic development, clinical biomarker assays, and pharma services through a CLIA-certified lab.

TypeDirect peer
Description

Molecular diagnostics company specializing in ctDNA-based MRD and oncology monitoring tests. Directly comparable to TrilliumBiO's Oncular™ MRD offering and its ctDNA-based molecular residual disease testing capabilities.

TypeDirect peer
Description

Liquid biopsy and ctDNA testing company with companion diagnostic partnerships. Comparable to TrilliumBiO in oncology molecular diagnostics and biopharma partnership models.

TypeDirect peer
Description

Full-service clinical diagnostics laboratory offering specialty testing across oncology, pulmonology, and rare diseases. Comparable to TrilliumBiO in multi-specialty LDT testing and biopharma partnership services.

TypeDirect peer
Description

Molecular diagnostics company developing companion diagnostics and hereditary disease tests. Comparable in offering proprietary biomarker tests commercialized through biopharma partnerships.

TypeDirect peer
Description

Molecular diagnostics and precision medicine company offering comprehensive biomarker profiling and biopharma partnership services. Comparable to TrilliumBiO's companion diagnostic development platform.

TypeDirect peer
Description

Genomic diagnostics company focused on specialty molecular tests for oncology and pulmonology. Comparable to TrilliumBiO's specialty test portfolio in pulmonology (aPAP, AATD) and oncology (Oncular).

TypeBroad incumbent
Description

Large incumbent clinical laboratory network offering routine and specialty diagnostic testing nationwide. Comparable as a broad-scale US clinical lab competitor and potential commercial partner to TrilliumBiO.

TypeBroad incumbent
Description

Largest US clinical laboratory offering routine and advanced diagnostics including rare disease and specialty testing. Comparable as a broad US lab incumbent that competes with TrilliumBiO for physician adoption and biopharma services contracts.

TypeBroad incumbent
Description

Specialty molecular diagnostics company offering comprehensive genomic profiling and biopharma companion diagnostic partnerships. Comparable in serving biopharma companion diagnostic development at scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TrilliumBiO

Diagnostic Laboratory Servicestrilliumbio.com

TrilliumBiO firmographics

Firmographics
Name
TrilliumBiO
Legal name
Trillium Health, LLC
Website
https://trilliumbio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

TrilliumBiO industry classification

Industry
Product category
Diagnostic Laboratory Services
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAE
Clinical Chemistry, Hematology & Coagulation Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Diagnostic test development
  • Companion diagnostics
  • Biomarker discovery services
  • Clinical laboratory testing
  • Rare disease diagnostics

Where TrilliumBiO is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TrilliumBiO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Laboratory Diagnostic Testing Services: TrilliumBiO processes over 500,000 samples annually through its multi-accredited, CLIA-certified laboratory. Revenue is generated through diagnostic testing fees charged to healthcare providers, health systems, and pharmaceutical partners for validated assay services.
  2. Pharmaceutical and Biotech Partnership Services: The company collaborates with biotech and pharma partners to develop, validate, and commercialize companion diagnostic assays. These partnerships involve co-development, assay validation, and clinical laboratory services supporting partner therapeutic development programs and regulatory submissions.
  3. Companion Diagnostic Development and Licensing: TrilliumBiO develops and validates novel diagnostic tests in conjunction with biopharma partners, commercializing them as Laboratory Developed Tests (LDT) through its own laboratory infrastructure, generating licensing and development fees from partners.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNo-cost diagnostic test for aPAP (autoimmune Pulmonary Alveolar Proteinosis)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

TrilliumBiO product offering

Product offering

Core offering

TrilliumBiO is a life sciences company that develops, validates, and commercializes diagnostic assays (Laboratory Developed Tests) through its multi-accredited, CLIA-certified, CAP-accredited, ISO 15189-accredited laboratory in Rockville, MD. It partners with biotech and pharmaceutical companies to co-develop companion diagnostics and provides biomarker discovery, assay validation, and clinical testing services to physicians and patients nationwide. Its portfolio includes specialized tests for autoimmune pulmonary alveolar proteinosis (aPAP ClearPath), alpha-1 antitrypsin deficiency (AlphaID), and uveal melanoma monitoring (Oncular), processing over 500,000 samples annually.

Product overview

TrilliumBiO is a biomarker discovery and translational diagnostics company operating a multi-accredited, CLIA-certified laboratory that has launched over 100 assays and processes over 500,000 samples annually. The company operates a platform-plus-services model offering a portfolio of specialized diagnostic tests including Oncular™ for uveal melanoma monitoring, AlphaID™ for alpha-1 antitrypsin deficiency screening, and aPAP ClearPath™ for autoimmune pulmonary alveolar proteinosis detection. Additional offerings include VEGF-D assay for LAM diagnosis, EMR integration workflows, and custom biomarker discovery services. The company collaborates with biopharma partners, academic medical centers, foundations, and patient advocacy groups to translate scientific discoveries into patient-ready diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • Oncular™: A uveal melanoma monitoring solution combining personalized digital PCR with cloud-based ctDNA analysis to track molecular residual disease, longitudinal ctDNA trends, and early molecular signals of treatment response or disease progression in metastatic uveal melanoma patients.
  • AlphaID™
  • aPAP ClearPath™

Products and services

  • Oncular™ A Laboratory Developed Test for uveal melanoma monitoring that provides real-time, quantitative assessment of circulating tumor DNA (ctDNA) from a blood draw, delivering molecular residual disease status, longitudinal ctDNA trends, and early molecular signals of treatment response or disease progression using personalized digital PCR with cloud-based data analysis.
  • AlphaID™ A diagnostic screening program for alpha-1 antitrypsin deficiency (AATD) that combines dried blood spot or buccal swab specimens with quantitative AAT serum measurement via immunoturbidimetry, detecting 14 clinically relevant SERPINA1 allelic variants including rare null alleles and compound heterozygotes missed by conventional testing.
  • aPAP ClearPath™ A GM-CSF autoantibody blood test for diagnosis of autoimmune pulmonary alveolar proteinosis (aPAP), available as both a serum-based assay and a dried blood spot (DBS) test that requires only a finger-prick sample. Developed and processed in partnership with Savara Inc., offered as a no-cost diagnostic tool to patients.
  • VEGF-D Assay A biomarker assay for lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, used for diagnosis and monitoring of LAM patients.

Quantifiable outcome

  • GM-CSF autoantibody assay achieved 100% clinical accuracy in a cohort of 40 subjects (negative cohort n=20, positive cohort n=20)
  • +4 more outcomes

Companies that use TrilliumBiO

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

TrilliumBiO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TrilliumBiO partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • OncobitcoreStrategic or Co-development Partner · 9 December 2025TrilliumBiO and Oncobit formed a strategic partnership to bring Oncobit's uveal melanoma monitoring solution to the United States. TrilliumBiO implements Oncobit's proprietary Personalized Monitoring (PM) platform, including cloud-based data interpretation software, to track circulating tumor DNA (ctDNA) dynamics in metastatic uveal melanoma patients. The partnership makes Oncobit's assay available nationwide through TrilliumBiO's multi-accredited laboratory, providing physicians with molecular residual disease information to support precise therapy decisions. In May 2026, the companies launched Oncular™ as the resulting product.
  • BioHub Maryland (Maryland Tech Council)supportingGTM or Marketing Partner · 3 November 2025TrilliumBiO joined BioHub Maryland, the workforce initiative powered by Maryland Tech Council, as an Elite Partner. This collaboration supports strengthening Maryland's life sciences ecosystem by highlighting career paths in laboratory medicine and expanding access to high-impact research and development opportunities. BioHub Maryland is a workforce initiative helping life sciences companies grow by showcasing career opportunities and providing access to talent and strategic resources.
  • T-NeuroDxcoreStrategic or Co-development Partner · 29 July 2025TrilliumBiO and T-NeuroDx announced a strategic collaboration to advance the development and commercialization of blood-based biomarker diagnostics for Alzheimer's disease. The partnership combines TrilliumBiO's diagnostic assay development and clinical validation expertise with T-NeuroDx's biomarker science for Alzheimer's disease pathology. The companies aim to co-develop and validate blood-based biomarkers that can support earlier diagnosis, commercializing T-Neuro's technology as a Lab Developed Test (LDT). The initiative includes clinical studies across diverse populations to support regulatory submissions.
  • Savara Inc.coreStrategic or Co-development Partner · 21 December 2023TrilliumBiO partnered with Savara Inc. as a CLIA-certified laboratory to develop and process the aPAP ClearPath GM-CSF autoantibody blood test for diagnosis of autoimmune pulmonary alveolar proteinosis (aPAP). The partnership developed both the serum-based assay and a dried blood spot (DBS) version using the ADX100 serum separator card. The test was offered as a simple, no-cost, noninvasive diagnostic tool to help confirm or rule out aPAP, addressing an estimated diagnosed prevalence of 7 cases per million in the US.
  • Grifols Shared Service North AmericacoreTechnology or IntegrationTrilliumBiO collaborates with Grifols on the AlphaID screening program for alpha-1 antitrypsin deficiency. The partnership uses Grifols' FDA-cleared AAT genotyping assay (Progenika Biopharma, Spain), which detects 14 clinically relevant SERPINA1 allelic variants. TrilliumBiO provides dried blood spot and buccal swab specimen processing, quantitative AAT measurement via immunoturbidimetry, and nationwide testing logistics.
  • Cincinnati Translational Pulmonary Science CentersupportingStrategic or Co-development PartnerTrilliumBiO developed the dried blood spot GM-CSF autoantibody assay in collaboration with Savara Inc. and Cincinnati Translational Pulmonary Science Center. The study involved three independent analyses demonstrating robust analytical precision and strong correlations between serum from venipuncture and DBS samples.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

TrilliumBiO competitors and assessment

Company assessment

Direct peers

  • NeoGenomics Laboratories: Specialty clinical laboratory focused on oncology-focused diagnostic testing and biomarker services for pharma partners. Closely comparable to TrilliumBiO in offering companion diagnostic development, clinical biomarker assays, and pharma services through a CLIA-certified lab.
  • Natera: Molecular diagnostics company specializing in ctDNA-based MRD and oncology monitoring tests. Directly comparable to TrilliumBiO's Oncular™ MRD offering and its ctDNA-based molecular residual disease testing capabilities.
  • Guardant Health: Liquid biopsy and ctDNA testing company with companion diagnostic partnerships. Comparable to TrilliumBiO in oncology molecular diagnostics and biopharma partnership models.
  • BioReference Laboratories (OPKO Health): Full-service clinical diagnostics laboratory offering specialty testing across oncology, pulmonology, and rare diseases. Comparable to TrilliumBiO in multi-specialty LDT testing and biopharma partnership services.
  • Myriad Genetics: Molecular diagnostics company developing companion diagnostics and hereditary disease tests. Comparable in offering proprietary biomarker tests commercialized through biopharma partnerships.
  • Caris Life Sciences: Molecular diagnostics and precision medicine company offering comprehensive biomarker profiling and biopharma partnership services. Comparable to TrilliumBiO's companion diagnostic development platform.
  • Veracyte: Genomic diagnostics company focused on specialty molecular tests for oncology and pulmonology. Comparable to TrilliumBiO's specialty test portfolio in pulmonology (aPAP, AATD) and oncology (Oncular).

Broad incumbents

  • Laboratory Corporation of America (LabCorp): Large incumbent clinical laboratory network offering routine and specialty diagnostic testing nationwide. Comparable as a broad-scale US clinical lab competitor and potential commercial partner to TrilliumBiO.
  • Quest Diagnostics: Largest US clinical laboratory offering routine and advanced diagnostics including rare disease and specialty testing. Comparable as a broad US lab incumbent that competes with TrilliumBiO for physician adoption and biopharma services contracts.
  • Foundation Medicine (Roche): Specialty molecular diagnostics company offering comprehensive genomic profiling and biopharma companion diagnostic partnerships. Comparable in serving biopharma companion diagnostic development at scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

TrilliumBiO social profiles

Digital presence

TrilliumBiO compliance and trust

Trust signal

Compliance5 records

TrilliumBiO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TrilliumBiO leadership team

Management profile

Number of profiles

Profiles5 records

TrilliumBiO funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TrilliumBiO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TrilliumBiO

What does TrilliumBiO do?

TrilliumBiO is a life sciences company that develops, validates, and commercializes diagnostic assays (Laboratory Developed Tests) through its multi-accredited, CLIA-certified, CAP-accredited, ISO 15189-accredited laboratory in Rockville, MD. It partners with biotech and pharmaceutical companies to co-develop companion diagnostics and provides biomarker discovery, assay validation, and clinical testing services to physicians and patients nationwide. Its portfolio includes specialized tests for autoimmune pulmonary alveolar proteinosis (aPAP ClearPath), alpha-1 antitrypsin deficiency (AlphaID), and uveal melanoma monitoring (Oncular), processing over 500,000 samples annually.

Is TrilliumBiO a public or private company?

TrilliumBiO is a private company. It is classified as unknown and is currently operating.

When was TrilliumBiO founded?

TrilliumBiO was founded in 2022. It employs 51 to 100 people.

Where is TrilliumBiO based?

TrilliumBiO is headquartered in Rockville, United States, in the North America region.

How does TrilliumBiO make money?

Three revenue lines are on record. Laboratory Diagnostic Testing Services are the primary driver. The others are pharmaceutical and Biotech Partnership Services and companion Diagnostic Development and Licensing.

Who are TrilliumBiO's main competitors?

Direct peers on record are NeoGenomics Laboratories, Natera, Guardant Health, BioReference Laboratories (OPKO Health), Myriad Genetics, Caris Life Sciences and Veracyte. Broad incumbents are Laboratory Corporation of America (LabCorp), Quest Diagnostics and Foundation Medicine (Roche).

Does TrilliumBiO have an API?

No public API is recorded for TrilliumBiO.

What industry is TrilliumBiO in?

TrilliumBiO's product category is Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories. Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACTrilliumBiO and The LAM Foundation Partner to Advance LAM Awareness and EducationTrilliumBiO and The LAM Foundation announced a partnership to raise awareness of lymphangioleiomyomatosis (LAM), a rare progressive lung disease primarily affecting women. As part of the collaboration, TrilliumBiO highlighted its newly developed LAMair™ VEGF-D blood test, which is now available nationwide to support earlier diagnosis of LAM. The organizations plan to develop educational resources for clinicians and patients to improve diagnostic pathways and patient outcomes.PR NewswireTrilliumBiO and The LAM Foundation Partner to Advance LAM Awareness and EducationTrilliumBiO announced a partnership with The LAM Foundation to raise awareness of lymphangioleiomyomatosis (LAM), a rare progressive lung disease primarily affecting women. As part of this collaboration, TrilliumBiO highlighted LAMair, a VEGF-D blood test it developed and is now making available to physicians and patients nationwide. The partnership aims to address the chronic underdiagnosis of LAM, where women typically experience symptoms for 3 to 5 years before receiving an accurate diagnosis.PR NewswireTrilliumBiO and The LAM Foundation Partner to Advance LAM Awareness and EducationTrilliumBiO and The LAM Foundation announced a partnership to raise awareness of lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The collaboration supports earlier diagnosis via LAMair, a VEGF-D blood test, and aims to improve diagnostic pathways. Both organizations will continue joint educational initiatives.NewswireTrilliumBiO and The LAM Foundation Partner to Advance LAM Awareness and EducationTrilliumBiO and The LAM Foundation announced a partnership to raise awareness of lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The collaboration supports earlier diagnosis via LAMair, a VEGF-D blood test, and educational initiatives. Both organizations aim to improve diagnostic pathways and patient outcomes.startupticker.chOncobit launches uveal melanoma assay with TrilliumBiO in the USOncobit launched Oncular, a blood-based uveal melanoma monitoring assay, in the US with TrilliumBiO. The assay uses personalized digital PCR to quantify circulating tumor DNA from a routine blood draw. Financial terms were not disclosed.PR NewswireTrilliumBiO and Oncobit Launch Advanced Uveal Melanoma Monitoring Solution in the U.S.TrilliumBiO and Oncobit launched Oncular, a uveal melanoma monitoring assay, in the U.S. through TrilliumBiO's CLIA-certified laboratory. The test uses digital PCR to measure circulating tumor DNA, providing molecular residual disease status and treatment response signals. It aims to expand access to advanced molecular testing for this rare cancer.PR NewswireTrilliumBiO and Oncobit Partner to Bring Novel Uveal Melanoma Monitoring Solution to the U.S.TrilliumBiO and Oncobit announced a strategic partnership to bring Oncobit's uveal melanoma monitoring solution to the United States, making it available nationwide through TrilliumBiO's multi-accredited laboratory. The collaboration integrates Oncobit's Personalized Monitoring platform, which tracks circulating tumor DNA dynamics to predict treatment response and progression in metastatic uveal melanoma patients. Both companies aim to address a largely underserved patient population by providing physicians with molecular residual disease information to support more precise therapy decisions.PR NewswireTrilliumBiO and T-NeuroDx Announce Strategic Collaboration to Commercialize Blood-Based Biomarkers for Alzheimer's DiseaseTrilliumBiO and T-NeuroDx announced a strategic collaboration to co-develop and validate blood-based biomarkers for earlier Alzheimer's diagnosis. The partnership will commercialize T-NeuroDx's technology as a Lab Developed Test and conduct clinical studies to support regulatory submissions. The companies aim to shift detection from late-stage confirmation to early, actionable insight.